Cyclopentanohydrophenanthrene Ring System Doai Patents (Class 514/169)
  • Patent number: 10772878
    Abstract: This disclosure concerns novel demethylpenclomedine analogs. Also disclosed are pharmaceutical compositions and methods for using such compositions to treat hyperproliferative disorders.
    Type: Grant
    Filed: December 29, 2017
    Date of Patent: September 15, 2020
    Assignee: Dekk-Tec, Inc.
    Inventor: Lee Roy Morgan
  • Patent number: 10729701
    Abstract: The invention relates to compounds of formula (I), to the pharmaceutical compositions comprising same, and to the use thereof in the treatment of bacterial, fungal, viral and parasitic infections or in the treatment of cancer in humans or animals. In formula (I), R1 and R2 are as defined in claim 1.
    Type: Grant
    Filed: March 11, 2016
    Date of Patent: August 4, 2020
    Assignee: VIRBAC
    Inventors: Jean-Michel Brunel, Jean-Pascal Marc
  • Patent number: 10722513
    Abstract: The present invention relates to compositions, methods and kits for the treatment of respiratory disease. In particular, the compositions, methods and kits are particularly useful, but not limited to, the treatment or prevention of exacerbations of asthma and chronic obstructive pulmonary disease. The present invention provides a method of treating or preventing a respiratory disease in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of an inhibitor of casein kinase 1, thereby treating or preventing a respiratory disease in a subject. The present invention also provides a method of treating or preventing a respiratory disease in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of an inhibitor of ALK5, thereby treating or preventing a respiratory disease in a subject, wherein the inhibitor is administered directly to the airway and/or lungs.
    Type: Grant
    Filed: March 23, 2016
    Date of Patent: July 28, 2020
    Assignee: THE UNIVERSITY OF MELBOURNE
    Inventors: Alastair Stewart, Christine Keenan, Trudi Harris
  • Patent number: 10689391
    Abstract: The present invention provides compounds of Formula (I), and pharmaceutically acceptable salts thereof, as well as pharmaceutical compositions comprising these compounds and methods of using these compounds to prevent or treat FXR-mediated or TGR5-mediated diseases or conditions.
    Type: Grant
    Filed: December 12, 2018
    Date of Patent: June 23, 2020
    Assignee: Enanta Pharmaceuticals, Inc.
    Inventors: Yat Sun Or, Jun Ma, Guoqiang Wang, Xuechao Xing, Ruichao Shen, Bin Wang
  • Patent number: 10668108
    Abstract: Disclosed are methods of treating or reducing the occurrence of a steatohepatitis disorder. The disorder may include, for example, NASH, parenteral nutrition associated liver disease (PNALD), or genetic forms of liver disease. The method may comprise the step of administering a composition comprising obeticholic acid to an individual in need thereof.
    Type: Grant
    Filed: November 3, 2017
    Date of Patent: June 2, 2020
    Assignee: CHILDREN'S HOSPITAL MEDICAL CENTER
    Inventors: Takanori Takebe, Rie Ouchi
  • Patent number: 10660905
    Abstract: A pharmaceutical two-phase admixture for topical application, transdermal or transmucosal, characterized by components in two phases, a liquid and a solid, adapted for topical application, transdermal or transmucosal, to various skin and/or mucosal surface areas of the body is disclosed. The solid phase is comprised of one or more bio-identical hormones and the liquid phase is comprised of one or more excipient carrier oils. The bio-identical hormone component is comprised of one or more of Bi-Est, testosterone, progesterone, and dehydroepiandrosterone. The excipient carrier oil component is comprised of one or more of jojoba oil, evening primrose oil, and borage seed oil. The pharmaceutical admixture is especially useful in a regime of hormone replacement therapy.
    Type: Grant
    Filed: March 18, 2019
    Date of Patent: May 26, 2020
    Assignee: THE MENOPAUSE METHOD, INC.
    Inventors: Daved Rosensweet, Joshua B. Rosensweet
  • Patent number: 10646500
    Abstract: The present patent application relates to a method of treating allergic rhinitis in a subject (preferably a human) by administering a combination of mometasone or its salt and olopatadine or its salt.
    Type: Grant
    Filed: October 3, 2014
    Date of Patent: May 12, 2020
    Assignee: GLENMARK SPECIALTY S.A.
    Inventors: Neelima Khairatkar-Joshi, Abhay Kulkarni, Dinesh Pradeep Wale, Vikram Mansingh Bhosale, Piyush Agarwal, Patrick Keohane, Sudeesh K. Tantry, Chad Oh
  • Patent number: 10639317
    Abstract: The disclosure provides a method of treating a patient having postpartum depression, premenstrual dysphoric disorder, menopausal depression, or delirium tremens comprising administering an effective amount of an injectable neurosteroid formulation to the patient. In certain embodiments the injectable neurosteroid formulation is an injectable ganaxolone formulation. Two types of injectable neurosteroid formulations may be used in the disclosed methods. The first such formulation is an injectable formulation containing ganaxolone and sulfobutyl ether ?-cyclodextrin in a 1:1 inclusion complex. The second such formulation is an injectable neurosteroid formulation comprising a neurosteroid, preferably ganaxolone, but which may be a neurosteroid selected from allopregnanolone, ganaxolone, alphaxalone, alphadolone, hydroxydione, minaxolone, pregnanolone, tetrahydrocorticosterone, and combinations of the foregoing; a surface stabilizer selected from hydroxyl ethyl starch, dextran, and povidone; and a surfactant.
    Type: Grant
    Filed: October 3, 2018
    Date of Patent: May 5, 2020
    Assignee: MARINUS PHARMACEUTICALS INC.
    Inventors: Christopher Cashman, Jaakko Lappalainen, David A Czekai
  • Patent number: 10548903
    Abstract: Novel methods for prevention, reduction or elimination of the incidence of male androgen deficiency symptoms or diseases including male hypogonadism-associated symptoms and diseases associated with low serum testosterone and/or low DHEA or low total androgens in susceptible warm-blooded animals including humans involving administration of an amount of a sex steroid precursor, particularly dehydroepiandrosterone (DHEA) and a selective estrogen receptor modulator (SERM) (particularly acolbifene), an antiestrogen or a prodrug of the two.
    Type: Grant
    Filed: June 19, 2017
    Date of Patent: February 4, 2020
    Assignee: Endorecherche, Inc.
    Inventors: Fernand Labrie, Sylvain Gauthier
  • Patent number: 10517930
    Abstract: The invention provides a method for alleviating discogenic pain by administering a therapeutic agent that disrupts neuronal and/or vascular elements in the disc, which is typically a degenerated disc. Disruption of neuronal elements in the disk includes destroying nerve endings without substantially affecting the central body of the nerve, suppressing activation of the nerve endings, and inhibiting the growth of nerve endings into the disk. Disruption of vascular elements includes causing the vascular extensions to retract from the disk, or suppressing the formation of such extensions. The therapeutic agent may be administered locally via an interbody pump, a bolus or a depot, or may be administered systemically.
    Type: Grant
    Filed: September 29, 2017
    Date of Patent: December 31, 2019
    Assignee: Warsaw Orthopedic, Inc.
    Inventors: Josee Roy, Susan J. Drapeau, Jeffrey C. Marx
  • Patent number: 10493115
    Abstract: Some embodiments of the present disclosure include a therapeutic extract for selectively treating skin disorders, such as acne and rosacea. The therapeutic extract may include glycerin; water, such as reverse osmosis water; blackcurrant; pine; gluconolactone; citric acid; and sodium benzoate. In embodiments, the blackcurrant may be organic ribes nigrum and may be derived from fruit of a blackcurrant plant. Moreover, the pine may be pinus spp and may be derived from a needle of a pine plant.
    Type: Grant
    Filed: October 21, 2016
    Date of Patent: December 3, 2019
    Inventor: Karen Drake
  • Patent number: 10485823
    Abstract: The present invention is directed to a method of treating cervical intraepithelial neoplasia by administering a composition containing poly-gamma-glutamic acid. According to the present invention, cervical intraepithelial neoplasia in unmarried women, pre-childbirth women, or women who do not want infertility, can be treated without concern about infertility.
    Type: Grant
    Filed: April 18, 2016
    Date of Patent: November 26, 2019
    Assignee: BIOLEADERS CORPORATION
    Inventors: Il-Han Lee, Seung Hoon Kim, Min Young Park
  • Patent number: 10471007
    Abstract: Supplement formulations of estrogen blocker, glycogen manager, and muscle recovery solutions and sublingual therapies for increasing absorption rates thereof. The sublingual delivery systems allow the body to absorb up to 94.9% of each dose directly into the bloodstream, completely bypassing the digestion process. Sublingual delivery (under the tongue) results in potencies 4 to 5 times greater than most capsules and powders. An estrogen blocker solution includes purified water, vegetable glycerin, polypropylene glycol, potassium benzoate, citric acid, calcium D glucarate, 7 keto DHEA, IO3, DIM, nettle root extract, Agaricus biporus extract, narigin extract, and quercetin dehydrate. Formulas for glycogen manager, and muscle recovery are also disclosed.
    Type: Grant
    Filed: April 4, 2017
    Date of Patent: November 12, 2019
    Inventor: Jeffrey R Olynyk
  • Patent number: 10441592
    Abstract: The present invention relates to the use of a combination of a PDE5-inhibitor and testosterone for the preparation of a medicament for the treatment of Female Sexual Dysfunction.
    Type: Grant
    Filed: June 12, 2017
    Date of Patent: October 15, 2019
    Assignee: EB IP LYBRIDO B.V.
    Inventor: Jan Johan Adriaan Tuiten
  • Patent number: 10421774
    Abstract: Compounds having drug and bio-affecting properties, their pharmaceutical compositions and methods of use are set forth. In particular, betulinic acid derivatives that possess unique antiviral activity are provided as HIV maturation inhibitors, as represented by compounds of Formula I: These compounds are useful for the treatment of HIV and AIDS.
    Type: Grant
    Filed: February 2, 2017
    Date of Patent: September 24, 2019
    Assignee: ViiV HEALTHCARE UK (NO.5) LIMITED
    Inventors: Jie Chen, Yan Chen, Ira B. Dicker, Richard A. Hartz, Nicholas A. Meanwell, Beata Nowicka-Sans, Alicia Regueiro-Ren, Sing-Yuen Sit, Ny Sin, Jacob Swidorski, Brian Lee Venables
  • Patent number: 10376588
    Abstract: The invention provides stabilized aqueous pharmaceutical etanercept compositions suitable for long-term storage of etanercept, methods of manufacture of these compositions, methods of administration, and kits containing same.
    Type: Grant
    Filed: March 9, 2018
    Date of Patent: August 13, 2019
    Assignee: Coherus Biosciences, Inc.
    Inventors: Mark Manning, Brian Murphy
  • Patent number: 10342810
    Abstract: Provided herein are 19-nor C3,3-disubstituted C21-pyrazolyl steroids of Formula (I): and pharmaceutically acceptable salts thereof; wherein , R1, R2, R3a, R3b, R4a, R4b, R5, R6, and R7 are as defined herein. Such compounds are contemplated useful for the prevention and treatment of a variety of CNS-related conditions, for example, treatment of sleep disorders, mood disorders, schizophrenia spectrum disorders, convulsive disorders, disorders of memory and/or cognition, movement disorders, personality disorders, autism spectrum disorders, pain, traumatic brain injury, vascular diseases, substance abuse disorders and/or withdrawal syndromes, and tinnitus.
    Type: Grant
    Filed: June 27, 2018
    Date of Patent: July 9, 2019
    Assignee: Sage Therapeutics, Inc.
    Inventors: Gabriel Martinez Botella, Boyd L. Harrison, Albert Jean Robichaud, Francesco G. Salituro, Richard Thomas Beresis
  • Patent number: 10258612
    Abstract: Disclosed are methods and compositions for treating or preventing a disease or disorder responsive to a decrease in baseline mitochondrial iron in a subject in need thereof. The methods typically include administering a pharmaceutical composition comprising a mitochondrial permeable iron chelator to the subject.
    Type: Grant
    Filed: July 13, 2016
    Date of Patent: April 16, 2019
    Assignee: Northwestern University
    Inventors: Hossein Ardehali, Hsiang-Chun Chang
  • Patent number: 10201611
    Abstract: The present invention relates to a method of treating or preventing estrogen-sensitive tumours in a mammal, said method comprising the administration of a therapeutically effective amount of an estrogenic component to said mammal, wherein the estrogenic component is selected from the group consisting of: substances represented by the following formula in which formula R1, R2, R3, R4 independently are a hydrogen atom, a hydroxyl group or an alkoxy group with 1-5 carbon atoms; precursors capable of liberating a substance according to the aforementioned formula when used in the present method; and mixtures of one or more of the aforementioned substances and/or precursors. The estrogenic component according to the invention does not have undesirable proliferative effects on breast and/or endometrial tissue and displays sufficient estrogenicity to prevent that its administration will lead to hypoestrogenism and/or climacteric complaints.
    Type: Grant
    Filed: January 20, 2015
    Date of Patent: February 12, 2019
    Assignee: DONESTA BIOSCIENCE B.V.
    Inventors: Herman Jan Tijmen Coelingh Bennink, Evert Johannes Bunschoten
  • Patent number: 10201569
    Abstract: Novel multi-component formulations, procedures and methods for use in treating neuropathology and neurodegeneration incident to trauma are provided. Multi-component formulations of the invention comprise biologically active forms of any two, any three, or all four of at least one neurosteroid or neuroactive steroid, such as progesterone or synthetic progestin, at least one anti-epileptic or anticonvulsant, such as gabapentin, pregabalin or valproic acid, at least one NK-1 receptor antagonist, such as aprepitant, casopitant or vestipitant, at least one lithium-containing or lithium-related drug. The provided formulations are configured or adapted to prevent or reduce the incidence and severity of neurological damage caused by trauma, or the risk of such damage.
    Type: Grant
    Filed: October 23, 2015
    Date of Patent: February 12, 2019
    Assignee: Sapna Life Sciences Corporation
    Inventor: James Lorne Henry
  • Patent number: 10076483
    Abstract: The invention relates to the use of a steroid-3-carboxylic acid ester, a steroid-4 carboxylic acid ester or a steroid-17 carboxylic acid ester of a steroid, selected from the group of androstanones, androst-4-ene-diones, androst-5-ene-diones, dehydroepiandrosterones, androstenetriones or testosterones, with an acyl group of the carboxylic acid ester where R is selected from alkyl with at least two carbon atoms or cycloalkyl, or with the use of a compound containing these steroid carboxylic acid esters for local topical application for cosmetic or dermatological purposes. Moreover, this invention also relates to steroid carboxylic acid esters and their compounds used for local topical application.
    Type: Grant
    Filed: October 15, 2014
    Date of Patent: September 18, 2018
    Assignee: Chelac Holding GmbH
    Inventors: Heinrich Wieland, Marc A. Kessemeier, Ralf Zuhse
  • Patent number: 10053415
    Abstract: This invention is directed to methods of preparing AQX-1125 having the formula: This invention is also directed to intermediates utilized in the methods of preparing AQX-1125.
    Type: Grant
    Filed: January 20, 2017
    Date of Patent: August 21, 2018
    Assignee: Aquinox Pharmaceuticals (Canada) Inc.
    Inventors: Curtis Harwig, Jeyaprakashnarayanan Seenisamy, Mahesh Narayan Keregadde, Lakshindra Chetia
  • Patent number: 10016357
    Abstract: Personal lubricants containing royal jelly, a glow powder or xylitol are provided.
    Type: Grant
    Filed: March 22, 2013
    Date of Patent: July 10, 2018
    Assignee: THE BEAUTY FACTORY, LLC
    Inventors: Louis J. Rivers, IV, Kevin Stranen
  • Patent number: 9968591
    Abstract: Disclosed is a pharmaceutical composition for antifungal use, comprising: 1) one or more compounds selected from compounds represented by the general formula (1) below and physiologically acceptable salts thereof; 2) one or more compounds selected from polypropylene glycol, diesters of dibasic acids, triacetin, 2-ethyl-1,3-hexanediol, lauromacrogol, and polyoxyethylene-polyoxypropylene glycol; and 3) one or more compounds selected from glucono-?-lactone, propylene glycol, glycerin, and lactic acid. General formula (1) (In the formula, X represents a halogen or hydrogen). wherein X represents a halogen or hydrogen.
    Type: Grant
    Filed: November 12, 2014
    Date of Patent: May 15, 2018
    Assignees: Pola Pharma Inc., Nihon Nohyaku CO., LTD.
    Inventors: Takaaki Masuda, Naoto Nishida, Naoko Kobayashi, Hideaki Sasagawa
  • Patent number: 9943601
    Abstract: The invention provides stabilized aqueous pharmaceutical etanercept compositions suitable for long-term storage of etanercept, methods of manufacture of these compositions, methods of administration, and kits containing same.
    Type: Grant
    Filed: March 23, 2016
    Date of Patent: April 17, 2018
    Assignee: Coherus Biosciences, Inc.
    Inventors: Mark Manning, Brian Murphy
  • Patent number: 9931350
    Abstract: Cationic steroidal antimicrobials (“CSAs” or “ceragenins”) and methods of making and using the same. Particularly advantageous uses include treating infections in patient and sub-patient populations, especially those having a bone disease, a broken bone, a bone infection, or a bone implant.
    Type: Grant
    Filed: March 11, 2015
    Date of Patent: April 3, 2018
    Assignee: BRIGHAM YOUNG UNIVERSITY
    Inventors: Paul B. Savage, Carl Genberg
  • Patent number: 9884051
    Abstract: This disclosure concerns novel demethylpenclomedine analogs. Also disclosed are pharmaceutical compositions and methods for using such compositions to treat hyperproliferative disorders.
    Type: Grant
    Filed: August 16, 2016
    Date of Patent: February 6, 2018
    Assignee: Dekk-Tec, Inc.
    Inventor: Lee Roy Morgan
  • Patent number: 9844510
    Abstract: The invention relates to a pharmaceutical tablet for oral administration comprising ulipristal acetate together with the following excipients: at least one diluent in an amount of 50 to 98.5 wt %, at least one binding agent in an amount of 0 to 10 wt %, at least one disintegrating agent in an amount of 0.5 to 10 wt %, and at least one lubricant in an amount of 0 to 10 wt %.
    Type: Grant
    Filed: June 17, 2016
    Date of Patent: December 19, 2017
    Assignee: Laboratoire HRA-Pharma
    Inventors: Erin Gainer, Helene Guillard, Denis Gicquel, Marianne Henrion, Celine Gnakamene
  • Patent number: 9814732
    Abstract: The invention relates to the use of ulipristal acetate, or any of its metabolites, in preventing or treating a breast tumor in a patient, preferably a patient that carries a mutation in BRCA1 gene.
    Type: Grant
    Filed: July 29, 2016
    Date of Patent: November 14, 2017
    Assignees: Laboratoire HRA-PHARMA, INSERM (Institut National de la Sante et de la Recherche Medicale)
    Inventors: Michele Resche-Rigon, Delphine Levy, Erin Gainer, Anne Gompel, Patricia Forgez, Laudine Desreumaux-Communal
  • Patent number: 9737548
    Abstract: The invention relates to the field of female sexual dysfunction. It specifically relates to the influence of the combination of testosterone or an analog thereof and tadalafil on sexual health in female subjects with Female Sexual Dysfunction (such as Female Sexual Arousal Disorder (FSAD) or Female Sexual Desire Disorder (FSDD)). It further relates to the influence of the combination of testosterone or an analog thereof and a compound capable of at least in part inhibiting smooth muscle constriction, for example a compound capable of at least in part inhibiting the adrenergic tone. The invention further discloses other combinatorial therapies in the treatment of Female Sexual Dysfunction.
    Type: Grant
    Filed: April 1, 2016
    Date of Patent: August 22, 2017
    Assignee: EB IP LYBRIDO B.V.
    Inventors: Jan Johan Adriaan Tuiten, Johannes Martinus Maria Bloemers
  • Patent number: 9713621
    Abstract: The present invention provides a composition and method for treating endometriosis which generally, comprises a mixture of anabolic steroids and the administration of same. The first anabolic steroid used is stanozolol used in conjunction with nandralone. The composition is preferably deployed an as injectable liquid suspension. It is also possible to deploy the steroids used herein as an oral administration of the stanozolol alone with an injection of nandralone weekly or as a daily topical nandralone cream.
    Type: Grant
    Filed: June 4, 2015
    Date of Patent: July 25, 2017
    Inventor: Edward Lichten
  • Patent number: 9683009
    Abstract: Compounds and compositions for the treatment of bone disorders are presented.
    Type: Grant
    Filed: May 2, 2014
    Date of Patent: June 20, 2017
    Assignees: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC.
    Inventors: Farhad Parhami, Frank Stappenbeck, Michael E. Jung, William M. Pierce, Jr., Kevyn Merten, K. Grant Taylor
  • Patent number: 9669011
    Abstract: The invention provides methods for treating various conditions using derivatives of cyclopamine having the following formula:
    Type: Grant
    Filed: August 31, 2015
    Date of Patent: June 6, 2017
    Assignee: Infinity Pharmaceuticals, Inc.
    Inventors: Alfredo C. Castro, Michael J. Grogan, Karen J. McGovern, Martin R. Tremblay
  • Patent number: 9662278
    Abstract: The present invention discloses a root canal dental paste that has include a first portion made from at least one antibiotic compound and partially set calcium based cement which forms a matrix to at least partially encapsulate the antibiotic compound. The first portion is then ground and combined with a second portion being a non-setting material and an antibiotic to form a paste.
    Type: Grant
    Filed: January 31, 2014
    Date of Patent: May 30, 2017
    Inventor: Matthew Athanassiadis
  • Patent number: 9597336
    Abstract: In one aspect, the present invention provides neuroactive steroids for use in the treatment of nervous system disorders, degenerative brain diseases and congenital storage diseases. In a second aspect, the invention provides neuroactive steroids in combination with a Liver X Receptor (LXR) ligand to effect treatment of a nervous system condition.
    Type: Grant
    Filed: October 24, 2013
    Date of Patent: March 21, 2017
    Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventor: Synthia Mellon
  • Patent number: 9592043
    Abstract: Medical devices having more than one degradation zone or degradation mechanism are used for orthopedic repair devices and soft tissue fixation devices.
    Type: Grant
    Filed: March 11, 2010
    Date of Patent: March 14, 2017
    Assignee: Covidien LP
    Inventors: Joshua Stopek, Jonathan D. Thomas
  • Patent number: 9579329
    Abstract: The present invention relates to a new use of tetrahydroxylated estrogens such as estetrol (1,3,5(10)-estratrien-3, 15?, 16?, 17?-tetrol), namely in a method of emergency contraception. The method of emergency contraception according to the invention comprises the oral administration of estetrol in a single dose within 120 hours of sexual intercourse.
    Type: Grant
    Filed: August 9, 2012
    Date of Patent: February 28, 2017
    Assignee: Estetra S.P.R.L.
    Inventors: Wout Wouters, Herman Jan Tijmen Coelingh Bennink, Ludivine Petit, Jean-Michel Foidart
  • Patent number: 9556222
    Abstract: Disclosed herein are novel A-ring epoxidized triterpenoid compounds and derivatives thereof, including those of the formula (I), wherein the variables are defined herein. Also provided are pharmaceutical compositions, kits, and articles of manufacture comprising such compounds. Methods and intermediates useful for making the compounds, and methods of using the compounds, for example as antioxidant inflammation modulators, and compositions thereof are also provided.
    Type: Grant
    Filed: June 14, 2013
    Date of Patent: January 31, 2017
    Assignee: REATA PHARMACEUTICALS, INC.
    Inventors: Eric Anderson, Christopher F. Bender, Xin Jiang, Xiaofeng Liu, Haizhou Sun, Melean Visnick
  • Patent number: 9546194
    Abstract: This application is directed to the use of aminosteroid compounds for the selective inhibition of the enzyme PTP1B in a mammal for the treatment of diabetes.
    Type: Grant
    Filed: April 19, 2013
    Date of Patent: January 17, 2017
    Assignee: Ohr Pharmaceutical, Inc.
    Inventors: Michael McLane, Inez Ruiz-White, W. Lee Maloy, Henry R. Wolfe
  • Patent number: 9512165
    Abstract: Provided herein are 19-nor C3,3-disubstituted C21-pyrazolyl steroids of Formula (I), and pharmaceutically acceptable salts thereof; wherein, R1, R2, R3a, R3b, R4a, R4b, R5, R6, and R7 are as defined herein. Such compounds are contemplated useful for the prevention and treatment of a variety of CNS-related conditions, for example, treatment of sleep disorders, mood disorders, schizophrenia spectrum disorders, convulsive disorders, disorders of memory and/or cognition, movement disorders, personality disorders, autism spectrum disorders, pain, traumatic brain injury, vascular diseases, substance abuse disorders and/or withdrawal syndromes, and tinnitus.
    Type: Grant
    Filed: April 17, 2014
    Date of Patent: December 6, 2016
    Assignee: SAGE THERAPEUTICS, INC.
    Inventors: Gabriel Martinez Botella, Boyd L. Harrison, Albert Jean Robichaud, Francesco G. Salituro, Richard Thomas Beresis
  • Patent number: 9492412
    Abstract: The invention relates to an alcohol-free cosmetic or pharmaceutical foam composition comprising water, a hydrophobic solvent, a surface-active agent, a gelling agent, an active component selected from the group of urea, hydroxy acid and a therapeutic enhancer and a propellant. The foam further comprises active agents and excipients with therapeutic properties having enhanced skin penetration.
    Type: Grant
    Filed: April 22, 2014
    Date of Patent: November 15, 2016
    Assignee: Foamix Pharmaceuticals Ltd.
    Inventors: Dov Tamarkin, Doron Friedman, Meir Eini
  • Patent number: 9447139
    Abstract: The present invention relates to SHIP inhibitor compounds and methods for using these compounds. In particular, the present invention discloses the following methods: (i) a method of treating graft versus host disease in a subject; (ii) a method of inhibiting a SHIP1 protein in a cell; (iii) a method of selectively inhibiting a SHIP1 protein in a cell; (iv) a method for treating or preventing graft-versus-host disease (GVHD) in a recipient of an organ or tissue transplant; (v) a method of modulating SHIP activity in a cell expressing SHIP1 or SHIP2; (vi) a method of ex vivo or in vitro treatment of transplants; (vii) a method of inhibiting tumor growth and metastasis in a subject; (viii) a method of treating a hematologic malignancy in a subject; (ix) a method of inducing apoptosis of multiple myeloma cells; (x) a method of treating multiple myeloma in a subject; (xi) a method of inhibiting the proliferation of a human breast cancer cell; and (xii) a method of treating breast cancer in a subject.
    Type: Grant
    Filed: April 11, 2011
    Date of Patent: September 20, 2016
    Assignee: THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK
    Inventors: William G. Kerr, John D. Chisholm
  • Patent number: 9422241
    Abstract: This disclosure concerns novel demethylpenclomedine analogs. Also disclosed are pharmaceutical compositions and methods for using such compositions to treat hyperproliferative disorders.
    Type: Grant
    Filed: February 22, 2012
    Date of Patent: August 23, 2016
    Assignee: Dekk-Tec, Inc.
    Inventor: Lee Roy Morgan
  • Patent number: 9289382
    Abstract: According to various embodiments of this disclosure, pharmaceutical compositions comprising solubilized estradiol are provided. In various embodiments, such compositions are encapsulated in soft capsules which may be vaginally inserted for the treatment of vulvovaginal atrophy.
    Type: Grant
    Filed: February 17, 2015
    Date of Patent: March 22, 2016
    Assignee: TherapeuticsMD, Inc.
    Inventors: Brian A. Bernick, Julia M. Amadio
  • Patent number: 9248136
    Abstract: Hormone replacement therapies are provided comprising solubilized progesterone alone and optionally with an estrogen, cyclic/sequential and continuous-combined dosing, and administered via transdermal HRT delivery systems.
    Type: Grant
    Filed: January 25, 2013
    Date of Patent: February 2, 2016
    Assignee: TherapeuticsMD, Inc.
    Inventors: Brian A. Bernick, Julia M. Amadio, Peter H. R. Persicaner, Janice Louise Cacace, Neda Irani, Frederick D. Sancilio
  • Patent number: 9249180
    Abstract: Compounds having drug and bio-affecting properties, their pharmaceutical compositions and methods of use are set forth. In particular, alkyl and alkenyl C-3 modified betulinic acid derivatives that possess unique antiviral activity are provided as HIV maturation inhibitors, as represented by compounds of Formulas I, II, III and IV: a compound of Formula I a compound of Formula II a compound of Formula III and a compound of Formula IV The compounds are useful for the treatment of HIV and AIDS.
    Type: Grant
    Filed: February 21, 2014
    Date of Patent: February 2, 2016
    Assignee: Bristol-Myers Squibb Company
    Inventors: Jacob Swidorski, Yan Chen, Sing-Yuen Sit, Nicholas A. Meanwell, Alicia Regueiro-Ren, Jie Chen, Zheng Liu, Richard A. Hartz, Li Xu
  • Patent number: 9238037
    Abstract: Long term storage stable budesonide-containing solutions are disclosed. The solutions can include budesonide or a pharmaceutically acceptable salt thereof, cromolyn sodium, antioxidizing agent, benzoic acid, and a pharmaceutically acceptable fluid including propylene glycol and water. Kits including the long term storage stable budesonide-containing solutions and methods of treating ulcerative colitis are also disclosed.
    Type: Grant
    Filed: July 8, 2014
    Date of Patent: January 19, 2016
    Assignee: SciDose, LLC
    Inventors: Nagesh R. Palepu, Philip Christopher Buxton
  • Patent number: 9238035
    Abstract: The invention relates to the prophylactic and therapeutic applications of certain estrogenic components, such as estetrol, in neurological disorders, such as neonatal hypoxic-ischemic encephalopathy (HIE).
    Type: Grant
    Filed: April 8, 2013
    Date of Patent: January 19, 2016
    Assignee: UNIVERSITE DE LIEGE
    Inventors: Jean-Michel Foidart, Ekaterine Tskitishvili
  • Patent number: 9205092
    Abstract: Method of improving ovarian reserve in a human female with diminished ovarian reserve as measured by the female's anti-Müllerian hormone level. The method may include evaluating a first anti-Müllerian hormone level of the female, administering an androgen, such as dehydroepiandrosterone or testosterone, to the female for at least about one month, and then evaluating a second anti-Müllerian hormone level of the female. Change in the anti-Müllerian hormone level is indicative of change in the ovarian reserve, e.g., when the second anti-Müllerian hormone level is greater than the first anti-Müllerian hormone level, the ovarian reserve has improved. The androgen administration may continue until the second anti-Müllerian hormone level is greater than the first anti-Müllerian hormone level by a desired percentage or amount.
    Type: Grant
    Filed: June 27, 2013
    Date of Patent: December 8, 2015
    Inventors: Norbert Gleicher, David H. Barad, Dwyn V. Harben
  • Patent number: 9180133
    Abstract: The invention relates to a method for treating uterine fibroids, which method comprises administering to a patient in need thereof, an effective amount of 17?-acetoxy-11?-[4-N,N-dimethylamino-phenyl)-19-norpregna-4,9-diene-3,20-dione (ulipristal) or any metabolite thereof. More particularly, the method is useful for reducing or stopping bleeding in a patient afflicted with uterine fibroids, and/or for reducing the size of uterine fibroids.
    Type: Grant
    Filed: March 7, 2014
    Date of Patent: November 10, 2015
    Assignees: LABORATOIRE HRA-PHARMA, THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
    Inventors: Lynnette Nieman, Andre Ulmann, Diana Blithe, Erin Gainer